Exelixis, Inc. (EXEL)

収益の仕組み

Net product revenue is booked when US specialty distributors and pharmacies purchase Cabometyx and the smaller legacy drug Cometriq from Exelixis. Collaboration revenue is the royalty Exelixis earns as a percentage of Cabometyx sales made outside the US by Ipsen and Takeda, plus occasional milestone and license payments under those partnership agreements. Because one molecule drives both lines, group revenue effectively tracks the worldwide commercial performance of cabozantinib rather than a diversified drug portfolio.

セグメント別売上高

Cabometyx is protected by composition-of-matter and formulation patents that block direct generic copies today, and that protection is real. But it is time-limited and narrow rather than broad: Exelixis has already settled patent litigation setting a start date for generic entry in 2031, and the company depends on this one molecule rather than a wide portfolio of protected products.

Cabometyx treats cancer, a need that does not go away when the economy weakens, so prescription demand is largely insulated from the broader business cycle. The bigger swing factors are clinical and regulatory instead: approval in new cancer types, competition from rival oncology drugs, and treatment guideline changes move volumes far more than consumer spending patterns do.

主なリスク

• Reliance on a single molecule — The great majority of revenue comes from cabozantinib, sold as Cabometyx; the company's growth is dependent on the continued commercial success of this one franchise across its approved and future indications.
• Patent expiration and generic entry — Settlement agreements set generic versions of Cabometyx to enter the US market starting in 2031; once that happens, pricing pressure from generics and competing branded drugs is expected to pressure sales.
• Concentration among specialty distributors — Nearly all product reaches patients through a small number of specialty distributors and pharmacies; a disruption to, or renegotiation with, any one of them could affect a meaningful share of sales.
• Dependence on collaboration partners outside the US — Essentially all revenue generated outside the United States depends on Ipsen and Takeda commercializing cabozantinib effectively in their territories; a change in either partner's commercial effort directly reduces Exelixis's royalty income.